{"id":{"repo_id":"vt","oai_identifier":"oai:vtechworks.lib.vt.edu:10919/132452"},"canonical_url":"https://search.ndltd.org/etd/vt/oai:vtechworks.lib.vt.edu:10919/132452","repository":{"repo_id":"vt","name":"Virginia Tech","base_url":"https://vtechworks.lib.vt.edu/oai/request"},"display":{"title":"Elucidation of an oral drug delivery mechanism to the mammalian gastrointestinal tract via an engineered T4 phage","abstract":"Administration of oral biologics is hindered by the harsh nature of the upper gastrointestinal tract – e.g. low pH, proteases, etc. –, and patient noncompliance resulting from high dosing frequency, with an estimated 50% of chronically ill patients not adhering to the prescribed dosing regimen. Novel mechanisms of therapeutic production and delivery to the mammalian lower gastrointestinal tract (gut) have been previously described, creating engineered bacterial cells to colonize the gut microbiome and perpetually release peptides for symptom relief. Current iterations of this technology, however, maintain a plethora of disadvantages, including fitness and colonization defects. Bacteriophage (phage) are another dominant piece of the gut microbiome and coexist in the gastrointestinal tract with their bacterial hosts. This coexistence, and substantial production of protein upon infection, make them ideal candidates for genetic engineering and drug delivery. In the chapters below, we describe the generation of a recombinant phage capable of synthesizing and dispersing protein longitudinally in the mammalian gut when co-colonized with their bacterial prey, providing a methodology for continuous treatment of gastrointestinal disease. In Chapter I, we describe the bacteriophage lifecycle, use of bacterial cells to combat gastrointestinal diseases, prior methods of phage engineering, and mechanisms by which phage may be reimagined for long-term treatment applications within the gut microbiome, building upon limitations from previous technologies. In Chapter II, we demonstrate that T4 phages release a significant concentration of intracellular cytoplasmic material into the extracellular environment upon cell lysis, and that they are readily engineered to produce super-folding Green Fluorescent Protein (sfgfp). Creation of a small library of recombinant phages identified significant fluorescent signal above a wild-type (non-engineered) background for three phage-based promoters, selecting the late promoter gp22 for future engineering endeavors. We then expanded this technology to two diverse gastrointestinal diseases, ulcerative colitis and obesity, ameliorating symptoms via phage expression of serine protease inhibitor B1a (serpinB1a) and Escherichia coli clpB, respectively. Finally, murine health was examined to identify the safety of the proposed technology. A full body necropsy and serum panel of mice co-colonized with phage and their associated E. coli host, demonstrated no adverse health effects from the administration of engineered phage or heterologous protein production. Lastly, in Chapter III, we attempted to expand the therapeutic repertoire of our system by expressing proteins containing disulfide bonds. Preliminary feasibility measurements of protein localization to the periplasmic space and formation of disulfide bonds utilized the homodimeric and intramolecular disulfide bonded marker protein E. coli alkaline phosphatase (phoA). Assessment of PhoA production and translocation into the periplasmic space via a native E. coli phoA periplasmic localization signal sequence, was accomplished with the alkaline phosphatase colorimetric substrate p-nitrophenyl phosphate (pNpp). Phage-based PhoA demonstrated a significant increase in enzyme activity and protein production over a wild-type background, and compared to recombinant PhoA confined to the cytoplasm. Collectively, the creation of this system highlights a novel mechanism of oral delivery using engineered phage for the treatment of gastrointestinal disease.","abstract_html":"Administration of oral biologics is hindered by the harsh nature of the upper gastrointestinal tract – e.g. low pH, proteases, etc. –, and patient noncompliance resulting from high dosing frequency, with an estimated 50% of chronically ill patients not adhering to the prescribed dosing regimen. Novel mechanisms of therapeutic production and delivery to the mammalian lower gastrointestinal tract (gut) have been previously described, creating engineered bacterial cells to colonize the gut microbiome and perpetually release peptides for symptom relief. Current iterations of this technology, however, maintain a plethora of disadvantages, including fitness and colonization defects. Bacteriophage (phage) are another dominant piece of the gut microbiome and coexist in the gastrointestinal tract with their bacterial hosts. This coexistence, and substantial production of protein upon infection, make them ideal candidates for genetic engineering and drug delivery. In the chapters below, we describe the generation of a recombinant phage capable of synthesizing and dispersing protein longitudinally in the mammalian gut when co-colonized with their bacterial prey, providing a methodology for continuous treatment of gastrointestinal disease. In Chapter I, we describe the bacteriophage lifecycle, use of bacterial cells to combat gastrointestinal diseases, prior methods of phage engineering, and mechanisms by which phage may be reimagined for long-term treatment applications within the gut microbiome, building upon limitations from previous technologies. In Chapter II, we demonstrate that T4 phages release a significant concentration of intracellular cytoplasmic material into the extracellular environment upon cell lysis, and that they are readily engineered to produce super-folding Green Fluorescent Protein (sfgfp). Creation of a small library of recombinant phages identified significant fluorescent signal above a wild-type (non-engineered) background for three phage-based promoters, selecting the late promoter gp22 for future engineering endeavors. We then expanded this technology to two diverse gastrointestinal diseases, ulcerative colitis and obesity, ameliorating symptoms via phage expression of serine protease inhibitor B1a (serpinB1a) and Escherichia coli clpB, respectively. Finally, murine health was examined to identify the safety of the proposed technology. A full body necropsy and serum panel of mice co-colonized with phage and their associated E. coli host, demonstrated no adverse health effects from the administration of engineered phage or heterologous protein production. Lastly, in Chapter III, we attempted to expand the therapeutic repertoire of our system by expressing proteins containing disulfide bonds. Preliminary feasibility measurements of protein localization to the periplasmic space and formation of disulfide bonds utilized the homodimeric and intramolecular disulfide bonded marker protein E. coli alkaline phosphatase (phoA). Assessment of PhoA production and translocation into the periplasmic space via a native E. coli phoA periplasmic localization signal sequence, was accomplished with the alkaline phosphatase colorimetric substrate p-nitrophenyl phosphate (pNpp). Phage-based PhoA demonstrated a significant increase in enzyme activity and protein production over a wild-type background, and compared to recombinant PhoA confined to the cytoplasm. Collectively, the creation of this system highlights a novel mechanism of oral delivery using engineered phage for the treatment of gastrointestinal disease.","abstract_has_math":false,"creators":["Baker, Zachary Robert"],"institution":"Virginia Tech","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Biological Sciences","degree_department":"Biological Sciences","school":null,"contributors":[],"advisors":[],"committee_chairs":["Hsu, Bryan"],"committee_members":["Stevens, Ann M.","Caswell, Clayton C.","Li, Liwu"],"year":2025,"date_issued":"2025-05-13","date_published":"2025-05-13","updated_at":"2026-11-18T20:18:39Z","subjects":["Bacteriophage","Intestinal microbiome","Drug delivery","Phage engineering","Obesity","Inflammatory Bowel Disease"],"languages":["en"],"rights":["Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"identifier_entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["vt_gsexam:43391"],"render_values":[{"text":"vt_gsexam:43391","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/10919/132452","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/10919/132452","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://vtechworks.lib.vt.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Avtechworks.lib.vt.edu%3A10919%2F132452","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.committeechair","label":"Committee Chair","values":["Hsu, Bryan"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Stevens, Ann M.","Caswell, Clayton C.","Li, Liwu"]},{"key":"dc:contributor.department","label":"Department","values":["Biological Sciences"]},{"key":"dc:creator","label":"Author","values":["Baker, Zachary Robert"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-05-14T08:01:07Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-05-14T08:01:07Z"]},{"key":"dc:date.issued","label":"Date","values":["2025-05-13"]},{"key":"dc:publisher","label":"Institution","values":["Virginia Tech"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biological Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Virginia Polytechnic Institute and State University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Bacteriophage","Intestinal microbiome","Drug delivery","Phage engineering","Obesity","Inflammatory Bowel Disease"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by-nc-nd/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["vt_gsexam:43391"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/10919/132452"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Administration of oral biologics is hindered by the harsh nature of the upper gastrointestinal tract – e.g. low pH, proteases, etc. –, and patient noncompliance resulting from high dosing frequency, with an estimated 50% of chronically ill patients not adhering to the prescribed dosing regimen. Novel mechanisms of therapeutic production and delivery to the mammalian lower gastrointestinal tract (gut) have been previously described, creating engineered bacterial cells to colonize the gut microbiome and perpetually release peptides for symptom relief. Current iterations of this technology, however, maintain a plethora of disadvantages, including fitness and colonization defects. Bacteriophage (phage) are another dominant piece of the gut microbiome and coexist in the gastrointestinal tract with their bacterial hosts. This coexistence, and substantial production of protein upon infection, make them ideal candidates for genetic engineering and drug delivery. In the chapters below, we describe the generation of a recombinant phage capable of synthesizing and dispersing protein longitudinally in the mammalian gut when co-colonized with their bacterial prey, providing a methodology for continuous treatment of gastrointestinal disease. In Chapter I, we describe the bacteriophage lifecycle, use of bacterial cells to combat gastrointestinal diseases, prior methods of phage engineering, and mechanisms by which phage may be reimagined for long-term treatment applications within the gut microbiome, building upon limitations from previous technologies. In Chapter II, we demonstrate that T4 phages release a significant concentration of intracellular cytoplasmic material into the extracellular environment upon cell lysis, and that they are readily engineered to produce super-folding Green Fluorescent Protein (sfgfp). Creation of a small library of recombinant phages identified significant fluorescent signal above a wild-type (non-engineered) background for three phage-based promoters, selecting the late promoter gp22 for future engineering endeavors. We then expanded this technology to two diverse gastrointestinal diseases, ulcerative colitis and obesity, ameliorating symptoms via phage expression of serine protease inhibitor B1a (serpinB1a) and Escherichia coli clpB, respectively. Finally, murine health was examined to identify the safety of the proposed technology. A full body necropsy and serum panel of mice co-colonized with phage and their associated E. coli host, demonstrated no adverse health effects from the administration of engineered phage or heterologous protein production. Lastly, in Chapter III, we attempted to expand the therapeutic repertoire of our system by expressing proteins containing disulfide bonds. Preliminary feasibility measurements of protein localization to the periplasmic space and formation of disulfide bonds utilized the homodimeric and intramolecular disulfide bonded marker protein E. coli alkaline phosphatase (phoA). Assessment of PhoA production and translocation into the periplasmic space via a native E. coli phoA periplasmic localization signal sequence, was accomplished with the alkaline phosphatase colorimetric substrate p-nitrophenyl phosphate (pNpp). Phage-based PhoA demonstrated a significant increase in enzyme activity and protein production over a wild-type background, and compared to recombinant PhoA confined to the cytoplasm. Collectively, the creation of this system highlights a novel mechanism of oral delivery using engineered phage for the treatment of gastrointestinal disease."]},{"key":"dc:description.abstractgeneral","label":"General Abstract","values":["Current treatments of gastrointestinal (gut) disease are limited by high dosing frequency, patient noncompliance, and complications circumventing the harsh conditions of the upper gastrointestinal tract (e.g. stomach), leading to therapeutic degradation. Bacterial cells were previously explored as vectors for biologic delivery, yet cellular engineering approaches have traditionally lowered fitness and colonization potential of these microbial factories. As a result, recombinant bacteria are often outcompeted by the native gut flora, requiring high concentrations to alleviate disease pathology. These limitations support the need for novel mechanisms of treatment that improve oral delivery compliance and ease of use. Through the research described in this dissertation, we outline the potential to use bacteriophage as an alternative chassis for biologic production and delivery to the gastrointestinal tract, targeting and reducing symptoms of obesity and ulcerative colitis. Elucidation of this system presents a universal platform for the long-term amelioration of gastrointestinal disease through the use of lytic phage particles."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy"]},{"key":"dc:format.medium","label":"Dc Format Medium","values":["ETD"]},{"key":"dc:title","label":"Title","values":["Elucidation of an oral drug delivery mechanism to the mammalian gastrointestinal tract via an engineered T4 phage"]}]}],"canonical_facts":{"dc:contributor.committeechair":["Hsu, Bryan"],"dc:contributor.committeemember":["Stevens, Ann M.","Caswell, Clayton C.","Li, Liwu"],"dc:contributor.department":["Biological Sciences"],"dc:creator":["Baker, Zachary Robert"],"dc:date.accessioned":["2025-05-14T08:01:07Z"],"dc:date.available":["2025-05-14T08:01:07Z"],"dc:date.issued":["2025-05-13"],"dc:description.abstract":["Administration of oral biologics is hindered by the harsh nature of the upper gastrointestinal tract – e.g. low pH, proteases, etc. –, and patient noncompliance resulting from high dosing frequency, with an estimated 50% of chronically ill patients not adhering to the prescribed dosing regimen. Novel mechanisms of therapeutic production and delivery to the mammalian lower gastrointestinal tract (gut) have been previously described, creating engineered bacterial cells to colonize the gut microbiome and perpetually release peptides for symptom relief. Current iterations of this technology, however, maintain a plethora of disadvantages, including fitness and colonization defects. Bacteriophage (phage) are another dominant piece of the gut microbiome and coexist in the gastrointestinal tract with their bacterial hosts. This coexistence, and substantial production of protein upon infection, make them ideal candidates for genetic engineering and drug delivery. In the chapters below, we describe the generation of a recombinant phage capable of synthesizing and dispersing protein longitudinally in the mammalian gut when co-colonized with their bacterial prey, providing a methodology for continuous treatment of gastrointestinal disease. In Chapter I, we describe the bacteriophage lifecycle, use of bacterial cells to combat gastrointestinal diseases, prior methods of phage engineering, and mechanisms by which phage may be reimagined for long-term treatment applications within the gut microbiome, building upon limitations from previous technologies. In Chapter II, we demonstrate that T4 phages release a significant concentration of intracellular cytoplasmic material into the extracellular environment upon cell lysis, and that they are readily engineered to produce super-folding Green Fluorescent Protein (sfgfp). Creation of a small library of recombinant phages identified significant fluorescent signal above a wild-type (non-engineered) background for three phage-based promoters, selecting the late promoter gp22 for future engineering endeavors. We then expanded this technology to two diverse gastrointestinal diseases, ulcerative colitis and obesity, ameliorating symptoms via phage expression of serine protease inhibitor B1a (serpinB1a) and Escherichia coli clpB, respectively. Finally, murine health was examined to identify the safety of the proposed technology. A full body necropsy and serum panel of mice co-colonized with phage and their associated E. coli host, demonstrated no adverse health effects from the administration of engineered phage or heterologous protein production. Lastly, in Chapter III, we attempted to expand the therapeutic repertoire of our system by expressing proteins containing disulfide bonds. Preliminary feasibility measurements of protein localization to the periplasmic space and formation of disulfide bonds utilized the homodimeric and intramolecular disulfide bonded marker protein E. coli alkaline phosphatase (phoA). Assessment of PhoA production and translocation into the periplasmic space via a native E. coli phoA periplasmic localization signal sequence, was accomplished with the alkaline phosphatase colorimetric substrate p-nitrophenyl phosphate (pNpp). Phage-based PhoA demonstrated a significant increase in enzyme activity and protein production over a wild-type background, and compared to recombinant PhoA confined to the cytoplasm. Collectively, the creation of this system highlights a novel mechanism of oral delivery using engineered phage for the treatment of gastrointestinal disease."],"dc:description.abstractgeneral":["Current treatments of gastrointestinal (gut) disease are limited by high dosing frequency, patient noncompliance, and complications circumventing the harsh conditions of the upper gastrointestinal tract (e.g. stomach), leading to therapeutic degradation. Bacterial cells were previously explored as vectors for biologic delivery, yet cellular engineering approaches have traditionally lowered fitness and colonization potential of these microbial factories. As a result, recombinant bacteria are often outcompeted by the native gut flora, requiring high concentrations to alleviate disease pathology. These limitations support the need for novel mechanisms of treatment that improve oral delivery compliance and ease of use. Through the research described in this dissertation, we outline the potential to use bacteriophage as an alternative chassis for biologic production and delivery to the gastrointestinal tract, targeting and reducing symptoms of obesity and ulcerative colitis. Elucidation of this system presents a universal platform for the long-term amelioration of gastrointestinal disease through the use of lytic phage particles."],"dc:description.degree":["Doctor of Philosophy"],"dc:format.medium":["ETD"],"dc:identifier.other":["vt_gsexam:43391"],"dc:identifier.uri":["https://hdl.handle.net/10919/132452"],"dc:language.iso":["en"],"dc:publisher":["Virginia Tech"],"dc:rights":["Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by-nc-nd/4.0/"],"dc:subject":["Bacteriophage","Intestinal microbiome","Drug delivery","Phage engineering","Obesity","Inflammatory Bowel Disease"],"dc:title":["Elucidation of an oral drug delivery mechanism to the mammalian gastrointestinal tract via an engineered T4 phage"],"dc:type":["Dissertation"],"thesis:degree_discipline":["Biological Sciences"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Virginia Polytechnic Institute and State University"]},"updated_at":"2026-11-18T20:18:39Z"}